Abdullahi v. Pfizer was a lawsuit brought by Nigerian families against Pfizer, Inc. in U.S. federal court over a 1996 clinical trial in Kano, Nigeria, in which the company gave an experimental antibiotic to children during a meningitis epidemic without obtaining informed consent from their parents. The Second Circuit allowed the case to proceed under the Alien Tort Statute, ruling that non-consensual medical experimentation violates customary international law, and the dispute later ended in a settlement between Pfizer and the Kano state government.
What Happened in Kano in 1996
A severe meningitis epidemic hit Kano, Nigeria, in 1996. Pfizer set up a treatment center at the Infectious Disease Hospital and gave Trovafloxacin, an experimental antibiotic marketed as Trovan, to roughly 200 children. About half the children received Trovan. The other half received a low dose of Ceftriaxone, a standard meningitis treatment.1Justia. Abdullahi v. Pfizer, Inc., 562 F.3d 163 (2d Cir. 2009)
According to the families’ complaints, parents were never told their children were part of a clinical trial, and Pfizer did not obtain written informed consent. They also alleged that the company did not inform families that Doctors Without Borders was providing free treatment nearby. Eleven children died during the trial. Survivors were left with permanent brain damage, paralysis, deafness, and blindness.1Justia. Abdullahi v. Pfizer, Inc., 562 F.3d 163 (2d Cir. 2009)
How the Case Reached U.S. Federal Court
The families, represented by Rabi Abdullahi, filed suit in the Southern District of New York using the Alien Tort Statute, 28 U.S.C. § 1350. That statute gives federal district courts jurisdiction over civil claims brought by foreign citizens for torts committed in violation of a U.S. treaty or the “law of nations.”2Office of the Law Revision Counsel. 28 U.S.C. § 1350
The district court initially dismissed the case for lack of jurisdiction and on forum non conveniens grounds, suggesting Nigeria was the better venue. The Second Circuit Court of Appeals reversed that dismissal, allowed the case to move forward, and sent the venue question back to the lower court for reconsideration. The appellate ruling confirmed that American corporations can be held answerable in U.S. court for conduct abroad when that conduct breaches well-defined international rules.1Justia. Abdullahi v. Pfizer, Inc., 562 F.3d 163 (2d Cir. 2009)
Why Informed Consent Counted as International Law
The central legal question was whether the prohibition on non-consensual medical experimentation had risen to the level of customary international law. To qualify, the rule had to be clearly defined and widely accepted across nations, not merely an ethical preference.1Justia. Abdullahi v. Pfizer, Inc., 562 F.3d 163 (2d Cir. 2009)
The Second Circuit looked to the Nuremberg Code, which states that voluntary consent of the human subject is absolutely essential for medical experimentation, and to the Declaration of Helsinki, which sets ethical principles for research on human subjects. Together, these sources showed a global consensus that experimenting on people without their knowledge violates international standards. The court held that the rule was clear enough to support jurisdiction under the Alien Tort Statute.1Justia. Abdullahi v. Pfizer, Inc., 562 F.3d 163 (2d Cir. 2009)
That meant the families did not have to point to a specific Nigerian statute. They could rely on the universally recognized requirement of informed consent to establish the court’s power to hear the claims.1Justia. Abdullahi v. Pfizer, Inc., 562 F.3d 163 (2d Cir. 2009)
How the Case Was Resolved
After years of litigation in both Nigeria and the United States, Pfizer and the Kano state government reached a settlement to resolve the claims. The agreement provided:
- Funding for local healthcare infrastructure and medical improvements.
- Compensation for the families involved in the medical trials.
- Coverage for legal expenditures incurred during the dispute.
- Reimbursement to the state government for costs related to the case.1Justia. Abdullahi v. Pfizer, Inc., 562 F.3d 163 (2d Cir. 2009)